Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DENALI asthma study of PT027 versus PT008, PT007, and placebo
2018-003674-27Phase 3Completed
- Sponsor
- Bond Avillion 2 Development LP
- Start
- Feb 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salbutamol + budesonide, budesonide and salbutamol in asthma (5 arms), sponsored by Bond Avillion 2 Development LP. Primary endpoint: Dual-primary endpoints. Started Feb 2019; status: completed.
02
Drugs
salbutamol + budesonidebudesonidesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on 2018-003674-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003674-27.